研究内容Research content

Research Overview

Gastrointestinal (GI) diseases encompass a wide range of conditions affecting both hollow organs (esophagus, stomach, small intestine, colon) and solid organs (liver, pancreas). These include cancer, inflammatory diseases, and functional disorders. Although numerous therapeutic strategies have been developed, disease definitions are still largely based on macroscopic findings such as symptoms and endoscopic morphology. This has limited our ability to stratify patients biologically and has led to variable treatment responses among individuals. To elucidate the underlying mechanisms of these diseases at molecular and cellular levels, our lab propose a multifaceted approach incorporating the following three methodologies:

1. Immunological Analysis of GI Diseases
The gastrointestinal tract is rich in immune cells, especially within gut-associated lymphoid tissue (GALT). Dysregulation of immune cell interactions is thought to be central to the pathogenesis of many inflammatory and neoplastic GI diseases. We analyze patient-derived samples to investigate immune cell composition, activation status, and interactions, aiming to clarify the role of immune dysregulation in disease.
2. Single-cell and Spatial Transcriptomic Analysis with Live Imaging
Advanced technologies such as single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and two-photon intravital imaging enable us to investigate the transcriptomic profiles and spatial organization of individual cells within tissue. In combination with live imaging, this allows real-time tracking of immune and epithelial cell behavior, offering insight into the spatiotemporal orchestration of cellular functions during disease progression.
3. Microbiome and Metabolite-based Approaches
The intestinal microbiota plays a critical role in immune regulation, mucosal homeostasis, and host metabolism. Recent studies have revealed that microbial metabolites (e.g., short-chain fatty acids, biogenic amines) are key modulators of disease states. We perform 16S rRNA sequencing, metagenomics, and metabolomic profiling of patient-derived stool samples to elucidate the host–microbiota–metabolite axis in GI pathology.
 
By integrating these three approaches, we aim to decode the complex pathophysiology of gastrointestinal diseases and contribute to the development of precision medicine and novel therapeutic targets.